Table 4.
HSV Affected Eye n = 79 |
Contralateral Eye n = 79 |
Herpes Labialis Group n = 101 |
Healthy Controls n = 89 |
|||
---|---|---|---|---|---|---|
First Visit | Follow up | First Visit | Follow up | |||
CNFD n/mm2 | 2.5 ± 5.7 a,b1 | 6.5 ± 7.0 a,b6,c,e | 9.9 ± 7.6 a,b1 | 12.6 ± 10.3 a,b6,d | 19.1 ± 12.2 c,d | 15.8 ± 10.8 e |
CNBD n/mm2 | 2.7 ± 7.2 a,b1 | 8.1 ± 10.7 a,b6,c,e | 11.7 ± 13.5 a,b1 | 15.2 ± 16.2 a,b6 | 22.0 ± 20.7 c | 21.3 ± 24.2 e |
CNFL mm/mm2 | 6.3 ± 4.3 b1 | 7.3 ± 4.3 b6,c,e | 9.6 ± 6.3 a,b1,d,f | 9.7 ± 4.2 a,b6 | 12.8 ± 5.2 c,d | 11.9 ± 4.9 e,f |
CTBD n/mm2 | 20.1 ± 21.9 | 22.2 ± 18.5 c,e | 25.2 ± 20.6 a | 29.7 ± 25.6 a | 38.4 ± 31.2 c | 38.9 ± 34 e |
a,b1,b6,c,d,e,fp < 0.05 |
a—p value between parameters of the first visit and follow up; b1—p value between parameters of HSV affected and contralateral eyes during the first visit; b6—p value between parameters of HSV affected and contralateral eyes during follow up by Wilcoxon test; c—p value between parameters of HSV affected eye during follow up and herpes labialis group; d—p value between parameters of contralateral eye during follow up and herpes labialis group; e—p value between parameters of HSV affected eye during follow up and healthy controls; f—p value between parameters of contralateral eye during follow up and healthy controls by the Mann-Whitney test.